sarpogrelate has been researched along with Diabetic Nephropathies in 10 studies
sarpogrelate: structure given in first source
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20)." | 9.13 | Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008) |
| " We then investigated the effects of 24-month treatment with sarpogrelate hydrochloride, a 5-HT(A2) receptor antagonist, on urinary albumin level in 10 type 2 diabetics with microalbuminuria, compared with not treated control group." | 9.10 | Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. ( Haraguchi, T; Higashi, K; Kobori, S; Koga, N; Minami, J; Takahashi, T; Yano, M, 2002) |
| "Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20)." | 5.13 | Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008) |
| " We then investigated the effects of 24-month treatment with sarpogrelate hydrochloride, a 5-HT(A2) receptor antagonist, on urinary albumin level in 10 type 2 diabetics with microalbuminuria, compared with not treated control group." | 5.10 | Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. ( Haraguchi, T; Higashi, K; Kobori, S; Koga, N; Minami, J; Takahashi, T; Yano, M, 2002) |
| " Treatment with sarpogrelate improved ROS/NO imbalance in glomeruli, suppressed platelet aggregation in glomeruli, reduced platelet-derived microparticles, increased serum adiponectin level and reduced the level of albuminuria, compared with non-treated diabetic rats." | 3.74 | Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy. ( Arakawa, S; Fujimoto, S; Haruna, Y; Kashihara, N; Kobayashi, S; Komai, N; Namikoshi, T; Sasaki, T; Satoh, M; Tomita, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fouad Shalaby, MA | 1 |
| Abd El Latif, HA | 1 |
| El Yamani, M | 1 |
| Galal, MA | 1 |
| Kamal, S | 1 |
| Sindi, I | 1 |
| Masaood, R | 1 |
| Kim, SK | 1 |
| Kim, G | 1 |
| Choi, BH | 1 |
| Ryu, D | 1 |
| Ku, SK | 1 |
| Kwak, MK | 1 |
| Lee, ES | 1 |
| Lee, MY | 1 |
| Kwon, MH | 1 |
| Kim, HM | 1 |
| Kang, JS | 1 |
| Kim, YM | 1 |
| Lee, EY | 1 |
| Chung, CH | 1 |
| Yoo, H | 1 |
| Park, I | 1 |
| Kim, DJ | 1 |
| Lee, S | 1 |
| Takahashi, T | 1 |
| Yano, M | 1 |
| Minami, J | 1 |
| Haraguchi, T | 1 |
| Koga, N | 1 |
| Higashi, K | 1 |
| Kobori, S | 2 |
| Kobayashi, S | 1 |
| Satoh, M | 1 |
| Namikoshi, T | 1 |
| Haruna, Y | 1 |
| Fujimoto, S | 1 |
| Arakawa, S | 1 |
| Komai, N | 1 |
| Tomita, N | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Ogawa, S | 1 |
| Mori, T | 1 |
| Nako, K | 1 |
| Ishizuka, T | 1 |
| Ito, S | 1 |
| Ishimura, E | 1 |
| Nishizawa, Y | 1 |
| Emoto, M | 1 |
| Shoji, T | 1 |
| Inaba, M | 1 |
| Kawagishi, T | 1 |
| Morii, H | 1 |
| Kasho, M | 1 |
| Sakai, M | 1 |
| Sasahara, T | 1 |
| Anami, Y | 1 |
| Matsumura, T | 1 |
| Takemura, T | 1 |
| Matsuda, H | 1 |
| Shichiri, M | 1 |
| Shouzu, A | 1 |
| Nomura, S | 1 |
| Hayakawa, T | 1 |
| Omoto, S | 1 |
| Shimizu, H | 1 |
| Miyake, Y | 1 |
| Yonemoto, T | 1 |
| Fukuhara, S | 1 |
| Iwasaka, T | 1 |
| Nishikawa, M | 1 |
| Inada, M | 1 |
3 trials available for sarpogrelate and Diabetic Nephropathies
| Article | Year |
|---|---|
Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy.
Topics: Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glycated | 2002 |
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis Obliterans; Aspirin; Ch | 2008 |
Therapeutic effect of sarpogrelate, a new 5-hydroxytryptamine receptor 2A antagonist, on diabetic nephropathy and neuropathy.
Topics: Adult; Aged; Albuminuria; Diabetic Nephropathies; Diabetic Neuropathies; Female; Follow-Up Studies; | 1997 |
7 other studies available for sarpogrelate and Diabetic Nephropathies
| Article | Year |
|---|---|
Therapeutic activity of sarpogrelate and dopamine D
Topics: Animals; Blood Glucose; Bromocriptine; Cabergoline; Diabetes Mellitus, Experimental; Diabetic Nephro | 2021 |
Negative correlation of urinary miR-199a-3p level with ameliorating effects of sarpogrelate and cilostazol in hypertensive diabetic nephropathy.
Topics: Animals; Biomarkers, Pharmacological; Cilostazol; Diabetic Nephropathies; Disease Models, Animal; Hy | 2021 |
Sarpogrelate hydrochloride ameliorates diabetic nephropathy associated with inhibition of macrophage activity and inflammatory reaction in db/db mice.
Topics: Adiponectin; Adipose Tissue; Albuminuria; Animals; Body Weight; Cell Movement; Diabetic Nephropathie | 2017 |
Effects of sarpogrelate on microvascular complications with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathie | 2019 |
Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adiponectin; Albuminuria; Animals; Blood Platelets; Deoxyguanosine; Dia | 2008 |
Serotonin enhances the production of type IV collagen by human mesangial cells.
Topics: Cells, Cultured; Collagen; Diabetic Nephropathies; Glomerular Mesangium; Humans; Ketanserin; Kinetic | 1998 |
Effect of sarpogrelate hydrochloride on platelet-derived microparticles and various soluble adhesion molecules in diabetes mellitus.
Topics: Antigens, CD; Blood Platelets; Cell Adhesion Molecules; Diabetes Mellitus; Diabetic Nephropathies; D | 2000 |